The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-α
Abstract
Aim of the Study. To analyze the predictive value of the genetic polymorphisms in rs8099917 and rs12979860 loci of the IL28В gene for the assessment of the efficacy prognosis of the combined antiviral therapy on the basis of the standard Interferon of the patients with Chronic Hepatitis C (CHC).
Materials and Methods. The study of IL28B genetic polymorphisms was conducted in 66 patients with HCV who did not receive the treatment earlier. The 24- week or 48-week antiviral therapy by standard Interferon-α2b and Ribavirin was prescribed to all patients, taking into consideration the genotype of the HCV-infection. The analysis of the efficacy of the treatment was conducted on the basis of the assessment of the normalization of the biochemical cytolysis markers during and after the treatment as well as the availability of the rapid, early and stable virology response.
Results. Among the patients with 1-st HCV genotype, the favorable genotype IL28В of alleles rs12979860 and rs8099917 (СС/ТТ) were associated with consider- ably higher frequency of the stable virology response than different versions of unfavorable genotype IL28В. Among the patients who did not have 1-st genotype the polymorphisms of IL28B gene did not affect the efficacy of antiviral therapy .
Conclusion. The studies of genetic polymorphisms of the regions of human genome demonstrates that the positive predictive value of IL28B polymorphisms among the patients with 1-st HCV genotype is higher than among the patients with 2nd and 3d genotypes. This kind of approach enables to take into account the pharmaco-economic aspect of the treatment of chronic HCV-infection.
About the Authors
A. V. Lapshin
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
M. V. Mayevskaya
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. T. Ivashkin
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
P. O. Bogomolov
M.F. Vladimirsky Moscow Region Research Clinical Institute
Russian Federation
Russian Federation
I. G. Nikitin
The Russian National Research Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
O. O. Znoyko
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Russian Federation
References
1. Болезни печени и желчевыводящих путей / Под ред. В.Т. Ивашкина. – М.: М-Вести, 2005. – С. 134–150.
2. Сюткин В.Е., Чуланов В.П., Карандашова И.В. и др. Влияние полиморфизма интерлейкина 28В на раннюю кинетику HCV у больных, получающих противовирусную терапию после ортотопической трансплантации печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2011. – Т.21, № 6. – С. 49–55.
3. Ющук Н.Д., Климова Е.А., Знойко О.О. и др. Протокол диагностики и лечения больных вирусными гепатитами В и С // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2010. – Т. 20, № 6. – С. 4–60.
4. Carithers R.L.Jr., Emerson S.S. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials // Hepatology. – 1997. – Vol. 26, N 3 (suppl. 1). – P. 83–88.
5. Chany M.G. et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases // Hepatology. – 2011. – Vol. 54, N 4. – P. 1433–1444.
6. Craxi A. EASL Clinical Practice Guidelines: management of hepatitis C virus infection // J Hepatology. – 2011 – Vol. 55, N 2. – P. 245–264.
7. Ge D., Fellay J., Thompson A.J. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance // Nature. – 2009. – Vol. 461, N 7262. – P. 399–401.
8. Grebely J., Petoumenos K., Hellard M. et.al. Potential role for interleukin-28B genotype in treatment decisionmaking in recent hepatitis C virus infection // Hepatology. – 2010. – Vol. 52, N 4. – P. 1216–1224.
9. Kempuraj D., Donelan J., Frydas S. et al. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities // Int. J. Immunopathol. Pharmacol. – 2004. – Vol. 17, N 2. – P. 103–106.
10. Marcellin P., Bourliere M., Pawlotsky J.M. et al. HCV non-responder patients: definition of non-response and treatment strategy // Gastroenterol. Clin. Biol. – 2007. – Vol. 31, N 8–9 (pt. 3). – P. 13–19.
11. Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study // Gastroenterology. – 2010. – Vol. 138, N 4. – P. 1331–1345.
12. Stattermayer A.F., Stauber R., Hofer H. et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C // Clin. Gastroenterol. Hepatol. – Vol. 9, N 4. – P. 344–350.
13. Suppiah V., Moldovan M., Ahlenstiel G. et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy // Nature genetics. – 2009. – Vol. 41, N 10. – P. 1100–1104.
Review
For citations:
Lapshin A.V., Mayevskaya M.V., Ivashkin V.T., Bogomolov P.O., Nikitin I.G., Znoyko O.O. The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-α. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;23(1):23-29. (In Russ.)
Views:
103
Email this article 
